SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CALABRO', Luana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.186
NA - Nord America 3.102
EU - Europa 1.095
SA - Sud America 590
Continente sconosciuto - Info sul continente non disponibili 119
AF - Africa 72
OC - Oceania 4
Totale 8.168
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.904
SG - Singapore 1.241
CN - Cina 448
BR - Brasile 438
IT - Italia 436
VN - Vietnam 401
HK - Hong Kong 370
BD - Bangladesh 277
DE - Germania 118
FR - Francia 99
JP - Giappone 99
GB - Regno Unito 97
ID - Indonesia 97
RU - Federazione Russa 92
CA - Canada 89
IN - India 82
FI - Finlandia 77
MX - Messico 71
AR - Argentina 59
NL - Olanda 34
ZA - Sudafrica 32
UA - Ucraina 28
IQ - Iraq 25
TR - Turchia 25
PL - Polonia 23
EC - Ecuador 21
AT - Austria 19
VE - Venezuela 17
CO - Colombia 16
PH - Filippine 16
ES - Italia 13
SA - Arabia Saudita 13
KR - Corea 11
MY - Malesia 11
SE - Svezia 11
PK - Pakistan 10
PY - Paraguay 10
AE - Emirati Arabi Uniti 9
CL - Cile 9
JO - Giordania 8
LT - Lituania 8
MA - Marocco 8
BO - Bolivia 7
UY - Uruguay 7
CH - Svizzera 6
CR - Costa Rica 6
HN - Honduras 6
JM - Giamaica 6
UZ - Uzbekistan 6
DZ - Algeria 5
EG - Egitto 5
GT - Guatemala 4
KE - Kenya 4
NP - Nepal 4
PA - Panama 4
PE - Perù 4
TN - Tunisia 4
AL - Albania 3
AU - Australia 3
BE - Belgio 3
BG - Bulgaria 3
BY - Bielorussia 3
PS - Palestinian Territory 3
PT - Portogallo 3
RS - Serbia 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
AM - Armenia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BN - Brunei Darussalam 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
GA - Gabon 2
IL - Israele 2
KH - Cambogia 2
KW - Kuwait 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
MK - Macedonia 2
NI - Nicaragua 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
AO - Angola 1
BB - Barbados 1
BF - Burkina Faso 1
BJ - Benin 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GE - Georgia 1
GM - Gambi 1
GN - Guinea 1
GR - Grecia 1
GY - Guiana 1
Totale 8.033
Salva come PNG Salva come JPEG
Città #
Singapore 680
Ashburn 525
Santa Clara 455
San Jose 410
Hong Kong 368
Council Bluffs 208
Ho Chi Minh City 146
Beijing 107
Hanoi 103
Tokyo 95
New York 82
Jakarta 74
Lauterbourg 73
Los Angeles 70
Helsinki 61
Mexico City 50
Milan 49
Chicago 42
Dallas 41
Chandler 40
São Paulo 40
Bologna 38
Toronto 34
London 30
Buffalo 28
Rome 26
Nuremberg 25
Orem 21
Munich 19
Da Nang 18
Ferrara di Monte Baldo 18
Hefei 18
Phoenix 18
Salt Lake City 18
Warsaw 18
Falkenstein 17
Haiphong 17
Montreal 17
Shanghai 17
Brooklyn 15
Denver 14
Hải Dương 14
Johannesburg 14
Brasília 13
Florence 13
New Delhi 13
Baghdad 12
Rio de Janeiro 12
San Francisco 12
Atlanta 11
Biên Hòa 11
Lappeenranta 11
Moscow 11
Naples 11
Seattle 11
Avon 10
Charlotte 10
Chennai 10
Elk Grove Village 10
Ferrara 10
Frankfurt am Main 10
Stockholm 10
Dhaka 9
Quito 9
Vienna 9
Amman 8
Boston 8
Düsseldorf 8
Guangzhou 8
Guayaquil 8
Paris 8
Amsterdam 7
Belo Horizonte 7
Houston 7
Kuala Lumpur 7
Montevideo 7
Santiago 7
Turin 7
Ankara 6
Assago 6
Asunción 6
Buenos Aires 6
Bến Tre 6
Curitiba 6
Figino 6
Fortaleza 6
Hounslow 6
Manchester 6
Philadelphia 6
Poplar 6
San José 6
Yongsan-gu 6
Can Tho 5
Columbus 5
Guarulhos 5
Hangzhou 5
Jeddah 5
Juiz de Fora 5
Manaus 5
Miami 5
Totale 4.632
Salva come PNG Salva come JPEG
Nome #
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up 184
Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge 171
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 167
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 153
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 152
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 148
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study 140
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 139
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy 127
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial 127
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 123
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial 120
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy 115
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC 108
P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients 106
Biomarkers for immune checkpoint inhibitors--authors' reply 104
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival 103
Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014 103
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 103
Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer 101
Challenges in lung cancer therapy during the COVID-19 pandemic 101
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications 101
Circulating haemopoietic and endothelial progenitor cells are decreased in COPD 100
Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignancies 99
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 98
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 97
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study 96
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases 95
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 95
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study 94
"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015 94
The emerging role of cancer nanotechnology in the panorama of sarcoma 91
Cancer bio‑immunotherapy XVI annual NIBIT‑(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy 89
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 87
Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center 86
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870.893 86
Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis 84
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study 83
COVID and Lung Cancer 83
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 82
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial 78
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial 77
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 76
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 76
Markers of endothelial and platelet status in patients with essential thrombocytemia and polycythemia vera 75
Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013 74
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer 74
Profilo lipidico nelle neoplasie ematologiche [Lipid profile in haematological malignancies] 71
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 71
The future of mesothelioma treatment: time to shift gear 70
Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications 69
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 68
Differential levels of solubile angiopoietin-2 and Tie-2 in patients with haematological malignancies 68
Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implication 68
Primary hepatic epithelioid hemangioendothelioma progressively responsive to Interferon-alpha: is there room for novel anti-angiogenetic treatments? 67
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy 67
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 66
Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line 66
Differential levels of solubile Endoglin (CD105) in myeloid malignancies 66
Increased concentration of circulating acid glycosaminoglycans in chronic lymphocytic leukemia and essential thrombocytaemia 66
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy 65
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 65
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 64
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 63
Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukaemia and long survival synthesize decorin 63
Ipilimumab experience in heavily pre-treated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 62
Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells 62
L'ipersplenismo: Attualità e prospettive [Hypersplenism: Current status and perspectives] 61
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease? 61
Methimazole-induced agranulocytosis and quick recovery with G-CSF: case report 61
Soluble angiogenic factors: implications for chronic myeloproliferative disorders 60
Levels of solubile angiogenin in chronic myeloid malignancies: clinical implications 59
DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy 57
Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population 57
Epigenetically regulated clonal heretability of CTA expression profiles in human melanoma 56
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients 56
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 56
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012 55
Epigenetic immunomodulation of hematopoietic malignancies 55
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 54
Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 54
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT) 53
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma 53
Expression and regulation of the B7-H3 receptor in human mesothelial and mesothelioma cells: a novel target for immunotherapeutic applications 52
Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain 52
Targeting of HLA-DR molecules transduces agonistic functional signals in Cutaneous melanoma 52
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 51
ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies 50
Thymosin α1 in melanoma from the clinical trial setting to the daily practice and beyond 50
Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study 47
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 47
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 47
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial 44
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010 43
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 41
The Effects of Variant Allele Frequency for EGFR Mutation on Early Tumor Shrinkage and Deepness of Response to Osimertinib in Patients with Metastatic Non-Small Cell Lung Cancer: An Exploratory Analysis 40
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 39
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 38
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients 35
Diagnostic accuracy of 18F-FDG PET/CT in muscle-invasive bladder cancer: rationale and design of the MIBC-PET study 30
Totale 7.958
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.565
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 345
Totale 61.910
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202234 0 0 0 0 0 0 0 0 0 0 0 34
2022/2023168 5 46 3 2 48 6 5 9 22 2 10 10
2023/2024260 10 47 21 13 19 4 4 15 9 13 20 85
2024/20251.877 81 125 172 29 237 234 67 53 198 398 173 110
2025/20265.341 370 206 484 614 672 184 563 309 499 625 501 314
2026/2027488 242 246 0 0 0 0 0 0 0 0 0 0
Totale 8.168